ABT Stock Recent News

ABT LATEST HEADLINES

ABT Stock News Image - zacks.com

Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?

zacks.com 2025 Jul 22
ABT Stock News Image - seekingalpha.com

14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.

seekingalpha.com 2025 Jul 22
ABT Stock News Image - marketbeat.com

If you wonder whether Abbott Laboratories NYSE: ABT is a good buy in Q2 2025, the answer is yes. The company's management, portfolio, cash flow, capital return, and pipeline are why.

marketbeat.com 2025 Jul 18
ABT Stock News Image - zacks.com

Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

zacks.com 2025 Jul 18
ABT Stock News Image - zacks.com

Abbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

zacks.com 2025 Jul 18
ABT Stock News Image - benzinga.com

Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.

benzinga.com 2025 Jul 18
ABT Stock News Image - seekingalpha.com

ABT, which had been outperforming the healthcare cohort from the S&P 500 and the S&P 500 itself all through this year, has slumped dramatically following yesterday's Q2 earnings. While Q2 sales beat expectations, with YoY growth rising to its highest point in 3 years, earnings merely met estimates, disappointing given the company's history of bottom-line beats averaging 9%. ABT's second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin guidance was cut, despite the company facilitating 100bps of improvements in Q2.

seekingalpha.com 2025 Jul 18
ABT Stock News Image - youtube.com

Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.

youtube.com 2025 Jul 17
ABT Stock News Image - youtube.com

Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.

youtube.com 2025 Jul 17
ABT Stock News Image - cnbc.com

Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was too extreme. "I think this is a little bit of an overreaction.

cnbc.com 2025 Jul 17
10 of 50